Neurocrine Biosciences Inc (NASDAQ:NBIX)
| 93.37 Delayed Data As of Apr 09 |  +0.67 / +0.73%Today’s Change | 86.02 Today|||52-Week Range 136.26 | -2.59% Year-to-Date |
Latest NBIX News | Press Releases
No recent news for Neurocrine Biosciences Inc.
Today’s Trading
| Previous close | 92.69 |
| Today’s open | 93.01 |
| Day’s range | 91.70 - 94.02 |
| Volume | 15,725 |
| Average volume (3 months) | 1,109,144 |
| Market cap | $9.2B |
Data as of 3:59pm ET, 04/09/2021
Growth & Valuation
| Earnings growth (last year) | +983.16% |
| Earnings growth (this year) | -22.03% |
| Earnings growth (next 5 years) | +18.10% |
| Revenue growth (last year) | +32.71% |
| P/E ratio | 22.4 |
| Price/Sales | 8.96 |
| Price/Book | 8.11 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CRSPCRISPR Therapeutics ... | -4.82 | -4.00% |
| XLRNAcceleron Pharma Inc | -2.30 | -1.78% |
| FATEFate Therapeutics In... | -1.18 | -1.49% |
| IBRXImmunitybio Inc | -1.84 | -9.84% |
Data as of 4:29pm ET, 04/09/2021
Financials
| Next reporting date | May 3, 2021 |
| EPS forecast (this quarter) | $0.55 |
| Annual revenue (last year) | $1.0B |
| Annual profit (last year) | $407.3M |
| Net profit margin | 38.94% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters San Diego, California |
Forecasts
